Lead Product(s) : Ifosfamide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ifoxa® by NanoAlvand Enhances Chemotherapy with Improved Side Effect Profile
Details : Ifoxa (ifosfamide) is a cytotoxic drug that binds to DNA and inhibit DNA synthesis. Ifoxa is indicated for the treatment of malignant diseases.
Product Name : Ifoxa
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 30, 2024
Lead Product(s) : Ifosfamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Introducing Vicrista® – A New Era in Pediatric Oncology
Details : Vicrista (vincristine sulphate) is a type of chemotherapy called a vinca alkaloid which interfere with microtubules and blocks cell growth by stopping mitosis. It is indicated for pediatric cancers.
Product Name : Vicrista
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 03, 2024
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endoxyna®; A Crucial Medication with A Novel Solution Formulation
Details : Endoxyna is a novel liquid formulation of cyclophosphamide, to replace the previous freeze-dried products. It is indicated for the treatment of cancer
Product Name : Endoxyna
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 29, 2024
Lead Product(s) : Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pomalidomide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pomavid®; Our Dedication to Shaping Hope
Details : Pomavid, a high-quality version of pomalidomide. Pomavid® is a new generation medication for the treatment of multiple myeloma, a type of blood cancer.
Product Name : Pomavid
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2024
Lead Product(s) : Pomalidomide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ozanimod
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Wellosia®; Prioritizing our Patients' Well-Being
Details : Wellosia (ozanimod) is a S1P modulator, small molecule drug candidate, which is indicated for the treatment of relapsing forms of multiple sclerosis & moderately to severely active ulcerative colitis.
Product Name : Wellosia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2021
Lead Product(s) : Ozanimod
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
NanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.
